Keratosis, Actinic Clinical Trial
Official title:
Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
Verified date | June 2017 |
Source | Bispebjerg Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Guidelines for photodynamic therapy (PDT) of actinic keratosis recommend pretreatment with curettage. The impact of curettage on the treatment effect is, however, not known. The present study aimed to evaluate whether daylight-PDT without curettage would reduce treatment effect compared to daylight-PDT with curettage.
Status | Completed |
Enrollment | 25 |
Est. completion date | December 20, 2017 |
Est. primary completion date | December 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Multiple actinic keratosis on the forehead or scalp Exclusion Criteria: - Known allergy to methyl aminolevulinate - Porphyria - Pregnancy - Lactation |
Country | Name | City | State |
---|---|---|---|
Denmark | Bispebjerg Hospital | Copenhagen NV | DK |
Lead Sponsor | Collaborator |
---|---|
Bispebjerg Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete lesion response rate | Complete lesion response rate, was defined as the number of completely responding lesions divided by the total number of treated lesion in each field. Complete lesion response was defined as complete disappearance of the lesion both by palpation and visually. | Treatment efficacy was evaluated 3 months after PDT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03076892 -
Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS
|
N/A | |
Terminated |
NCT03076918 -
Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy
|
N/A | |
Completed |
NCT05356572 -
A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin
|
N/A | |
Recruiting |
NCT05387525 -
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
|
Phase 4 | |
Completed |
NCT02594644 -
The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy
|
N/A | |
Active, not recruiting |
NCT02281682 -
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
|
Phase 4 | |
Completed |
NCT01458587 -
Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)
|
Phase 2 | |
Completed |
NCT05260073 -
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
|
||
Active, not recruiting |
NCT06014697 -
OCT and Invasion in Cutaneous Skin Lesions
|
||
Completed |
NCT05279131 -
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
|
Phase 3 | |
Completed |
NCT05481073 -
UV Sensor in Patients With Actinic Keratosis
|
||
Withdrawn |
NCT02813902 -
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
|
Phase 1 | |
Recruiting |
NCT05636800 -
Microwave Treatment for Actinic Keratosis
|
N/A | |
Completed |
NCT02628236 -
Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)
|
Phase 2 | |
Recruiting |
NCT06135415 -
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
|
Phase 3 | |
Completed |
NCT02644187 -
Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol
|
N/A | |
Completed |
NCT02281136 -
MUSE Study of Levulan Kerastick
|
Phase 2 | |
Completed |
NCT05060237 -
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
|
Phase 1 | |
Terminated |
NCT04269395 -
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
|
Phase 3 |